<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJO</journal-id>
<journal-title-group>
<journal-title>International Journal of Oncology</journal-title></journal-title-group>
<issn pub-type="ppub">1019-6439</issn>
<issn pub-type="epub">1791-2423</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ijo.2016.3748</article-id>
<article-id pub-id-type="publisher-id">ijo-49-06-2538</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>AKT/mTOR signaling pathway is involved in salvianolic acid B-induced autophagy and apoptosis in hepatocellular carcinoma cells</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Gong</surname><given-names>Ling</given-names></name><xref rid="af1-ijo-49-06-2538" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>Di</surname><given-names>Chunhong</given-names></name><xref rid="af2-ijo-49-06-2538" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>Xia</surname><given-names>Xiaofang</given-names></name><xref rid="af1-ijo-49-06-2538" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Jie</given-names></name><xref rid="af1-ijo-49-06-2538" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>Gongying</given-names></name><xref rid="af1-ijo-49-06-2538" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>Shi</surname><given-names>Junping</given-names></name><xref rid="af1-ijo-49-06-2538" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>Pengshuai</given-names></name><xref rid="af3-ijo-49-06-2538" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author">
<name><surname>Xu</surname><given-names>Hui</given-names></name><xref rid="af3-ijo-49-06-2538" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Weibing</given-names></name><xref rid="af3-ijo-49-06-2538" ref-type="aff">3</xref><xref ref-type="corresp" rid="c1-ijo-49-06-2538"/></contrib></contrib-group>
<aff id="af1-ijo-49-06-2538">
<label>1</label>Department of Liver Diseases, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang 310015, P.R. China</aff>
<aff id="af2-ijo-49-06-2538">
<label>2</label>Department of Laboratory, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang 310015, P.R. China</aff>
<aff id="af3-ijo-49-06-2538">
<label>3</label>Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China</aff>
<author-notes>
<corresp id="c1-ijo-49-06-2538">Correspondence to: Dr Weibing Zhang, Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, 2 NanBai Xiang, Wenzhou, Zhejiang 325000, P.R. China, E-mail: <email>zhangweibing1991@163.com</email></corresp></author-notes>
<pub-date pub-type="collection">
<month>12</month>
<year>2016</year></pub-date>
<pub-date pub-type="epub">
<day>24</day>
<month>10</month>
<year>2016</year></pub-date>
<volume>49</volume>
<issue>6</issue>
<fpage>2538</fpage>
<lpage>2548</lpage>
<history>
<date date-type="received">
<day>06</day>
<month>07</month>
<year>2016</year></date>
<date date-type="accepted">
<day>17</day>
<month>10</month>
<year>2016</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2016, Spandidos Publications</copyright-statement>
<copyright-year>2016</copyright-year></permissions>
<abstract>
<p>Chinese medicines are emerging as an attractive new generation of anticancer drugs. Here, we explored the impact of salvianolic acid B (Sal B), the major water-soluble compounds of Danshen, on apoptosis and autophagy of human hepatocellular carcinoma cells (HCC). We also investigated the related molecular mechanisms. We found that Sal B exhibits potent ability to inhibit HCC cells viability in a concentration-dependent manner, and to induce apoptosis via the mitochondrial apoptosis pathway. Additionally, Sal B could also induce autophagy. Furthermore, pretreatment with the autophagy inhibitor chloroquine or 3-methyladenine showed the potential in attenuating the apoptosis rate induced by Sal B. Mechanistically, Sal B treatment inhibited the AKT/mTOR signaling cascade <italic>in vitro</italic>. Overexpression of AKT abolished the effects of Sal B on HCC cells, suggesting a critical role of the AKT/mTOR signaling pathway in Sal B-induced biological effects. Our results indicated that the mitochondrial pathway was involved in Sal B-induced apoptosis of HCC cells. Moreover, the AKT/mTOR signaling pathway was involved in Sal B-induced autophagy, which promoted apoptosis. This study may provide a promising strategy for using Sal B as a chemotherapeutic agent for patients with HCC.</p></abstract>
<kwd-group>
<kwd>hepatocellular carcinoma</kwd>
<kwd>salvianolic acid B</kwd>
<kwd>AKT/mTOR signaling</kwd>
<kwd>apoptosis</kwd>
<kwd>autophagy</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the third cause of cancer mortality (<xref rid="b1-ijo-49-06-2538" ref-type="bibr">1</xref>,<xref rid="b2-ijo-49-06-2538" ref-type="bibr">2</xref>). HCC is associated with infection with hepatitis B and C virus. Most HCC patients are diagnosed at the late stage and lose the opportunity for surgical operation (<xref rid="b3-ijo-49-06-2538" ref-type="bibr">3</xref>). Conventional chemotherapy with oxaliplatin, doxorubicin, and fluorouracil as monotherapy or in combination for patients with advanced HCC is usually ineffective with a low response rate and severe side effects (<xref rid="b4-ijo-49-06-2538" ref-type="bibr">4</xref>&#x02013;<xref rid="b6-ijo-49-06-2538" ref-type="bibr">6</xref>). Sorafenib, a multitargeted tyrosine kinase inhibitor which has been shown to improve by 2.8 months the median overall survival (OS) and by 2.7 months the median progression-free survival (PFS) for unresectable HCC (<xref rid="b7-ijo-49-06-2538" ref-type="bibr">7</xref>). Currently, the prognosis of HCC is poor even with multidisciplinary comprehensive treatment. Therefore, identification and development of novel and safe treatment strategies are urgently needed to improve treatment outcomes.</p>
<p>In recent years, Chinese medicine is emerging as an attractive new generation of anticancer drugs due to their ability to effectively eliminate cancer cells with low toxicity (<xref rid="b8-ijo-49-06-2538" ref-type="bibr">8</xref>&#x02013;<xref rid="b10-ijo-49-06-2538" ref-type="bibr">10</xref>). <italic>Salvia miltiorrhiza</italic> (Danshen), a popular Chinese herb, has been widely used for treating angina pectoris, myocardial infarction (MI) and stroke (<xref rid="b11-ijo-49-06-2538" ref-type="bibr">11</xref>,<xref rid="b12-ijo-49-06-2538" ref-type="bibr">12</xref>). Salvianolic acid B (Sal B) is one of the major water-soluble compounds and active ingredients of Danshen (<xref rid="b13-ijo-49-06-2538" ref-type="bibr">13</xref>,<xref rid="b14-ijo-49-06-2538" ref-type="bibr">14</xref>). Recently, the anticancer effects of Sal B have been demonstrated in human cancer cell lines including prostate, breast, liver, and head and neck squamous cell cancers (<xref rid="b15-ijo-49-06-2538" ref-type="bibr">15</xref>&#x02013;<xref rid="b17-ijo-49-06-2538" ref-type="bibr">17</xref>). However, the effects of Sal B on HCC and the antitumor mechanisms have not been adequately studied.</p>
<p>Additionally, studies on the antitumor activity of Sal B have focused on inhibition of proliferation and induction of apoptosis (<xref rid="b15-ijo-49-06-2538" ref-type="bibr">15</xref>). Sal B has also been reported to induce autophagy (<xref rid="b18-ijo-49-06-2538" ref-type="bibr">18</xref>). Understanding the interplay between apoptosis and autophagy induced by Sal B in HCC may identify new targets for cancer therapy and improve the therapeutic efficiency of HCC. Currently, there are no reports on the effects of Sal B on the interplay between autophagy and apoptosis in HCC cells.</p>
<p>In this study, we demonstrated that Sal B inhibited the growth and induced cell death of human HCC cells <italic>in vitro</italic>. We also found that autophagy together with apoptosis is involved in Sal B-induced cell death in HCC cells. Inhibition of autophagy attenuated Sal B-induced cell death by reducing apoptosis. Moreover, Sal B-induced cell death was associated with AKT/mTOR signaling inhibition. These results suggest that Sal B could be a potential anticancer agent for the treatment of HCC.</p></sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title>Chemicals and antibodies</title>
<p>Sal B was purchased from Sigma (Sigma-Aldrich Corp., St. Louis, MO, USA). 3-MA and CQ were purchased from J&amp;K Chemical Ltd. (J&amp;K Chemical Ltd., Beijing, China). JC-1 and LysoTracker Red were obtained from Invitrogen (Guangzhou, China). The primary antibodies against LC-3, p62, Beclin-1, cleaved PARP, cleaved caspase-3, cytochrome <italic>c</italic>, total or phospho-AKT (Ser473), total or phospho-mTOR (Ser2448), phospho-4EBP1 (Thr70), and phospho-P70S6K (Thr389) were purchased from Cell Signaling Technology (Boston, MA, USA). The secondary antibodies were HRP-conjugated anti-rabbit IgG purchased from Cell Signaling Technology. The FITC-conjugated anti-rabbit IgG was purchased from Beyotime (Beyotime, Nantong, China).</p></sec>
<sec>
<title>Cells lines and cultures</title>
<p>SK-Hep-1 and Bel-7404 cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The cell lines were frozen in liquid nitrogen soon after arrival. The experiments with these cells were carried out within 6 generations after resuscitation. SK-Hep-1 and Bel-7404 cells were cultured in Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM), containing 10&#x00025; fetal bovine serum (FBS), 100 U penicillin and 100 U streptomycin at 37&#x000B0;C in a humidified incubator of 5&#x00025; CO<sub>2</sub> and 95&#x00025; air.</p></sec>
<sec>
<title>Cell viability assay</title>
<p>Cell proliferation was determined by MTS assay. Cells were seeded into 96-well plates and treated with Sal B, CQ, 3-MA or a combination. After treatment, 10 &#x003BC;l MTS (Promega) was added into each well for 2-h incubation. The absorbance was measured using a model ELX800 Microplate Reader (Bio-Tek Instruments, Inc., Winooski, VT, USA) at 490 nm to calculate the proliferation. Three independent experiments were performed to determine the half maximal inhibitory concentration values (IC<sub>50</sub>).</p></sec>
<sec>
<title>Colony forming assay</title>
<p>Cells were incubated at a density of 1,000 cells per well in 6-well plates and treated with a determined dose of Sal B or vehicle control for 2 weeks. After fixation with 4&#x00025; paraformaldehyde, the colonies formed were counterstained with crystal violet staining solution.</p></sec>
<sec>
<title>Apoptosis analysis</title>
<p>The cell apoptotic rate was determined by flow cytometry analysis using a fluorescein isothiocyanate (FITC) Annexin V Apoptosis Detection kit (KeyGen Biotech, Nanjing, China). Cells were collected by trypsinization, washed twice and resuspended in 1X binding buffer at a concentration of 1&#x000D7;10<sup>6</sup> cells/ml. Then, 100 &#x003BC;l of cells were mixed with 5 &#x003BC;l of FITC Annexin V and 5 &#x003BC;l PI and incubated for 15 min. The samples were sent out for analysis by flow cytometry. The results were analyzed with the BD FACSCalibur&#x02122; system.</p></sec>
<sec>
<title>Immunofluorescence analysis</title>
<p>Cells, seeded at 3&#x000D7;10<sup>5</sup> into 6-well culture plates, were treated with a determined dose of Sal B for indicated intervals and were incubated with Lyso Tracker for 60 min. Thereafter, cells were washed twice with PBS, followed by fixation in 4&#x00025; paraformaldehyde and permeabilized with 1&#x00025; CHAPS buffer (150 mM NaCl, 10 mM HEPES, 1.0&#x00025; CHAPS) at room temperature for 15 min. Hereafter, cells were incubated with anti-LC3 antibodies for 2 h at 37&#x000B0;C, and incubated with FITC-conjugated anti-rabbit IgG for 1 h at 37&#x000B0;C, and the cell nuclei were stained by DAPI (Invitrogen) for 15 min. Samples were examined under a Zeiss LSM 710 fluorescence microscopy system (Carl Zeiss Inc, Dublin, CA, USA). Images were processed with ZEN LE software. For quantification of LC3-positive cells, 150&#x02013;200 cells were randomly selected from the acquired images and counted. Cells with more than five dots of specific green or yellow signals were considered to be LC3-positive.</p></sec>
<sec>
<title>Transmission electron microscope</title>
<p>Cells, seeded at 3&#x000D7;10<sup>5</sup> into 6-well culture plates, were treated with a dose of 200 &#x003BC;M Sal B for 24 h. Then, the cells were washed and fixed for 30 min in 2.5&#x00025; glutaraldehyde. The samples were treated with 1.5&#x00025; osmium tetroxide, dehydrated with acetone and embedded in Durcupan resin. Thin sections were stained with lead citrate and examined by TECNAI 10 electron microscopy (Philips, Eindhoven, The Netherlands) at 60 kV.</p></sec>
<sec>
<title>RNA interference</title>
<p>For ATG6 (Beclin-1) interference, two siRNA oligonucleotides targeting ATG6 were synthesized by GenePharma (Shanghai, China). The sequences of the sense strands of the RNAs targeting ATG6 used in this study were as follows: ATG6 siRNA-1 (si1): 5&#x02032;-GUGAGAAGCAAGCCCU UAUTT-3&#x02032;, ATG6 siRNA-2 (si2): 5&#x02032;-CUCCAGUGCUAAGCUACAU-TT-3&#x02032;. A non-specific oligo that is not complementary to any human genes was used as a negative control. The mixture of si1 and si2 was used to increase the inhibitory activity. Cells were transfected with siRNA using HiPerFect (Qiagen) according to the manufacturer&#x02019;s protocol.</p></sec>
<sec>
<title>Plasmids transfection</title>
<p>The pcDNA3-AKT-T7 plasmid was a gift from William Sellers (Addgene plasmid 9003). Cells were seeded into 6-well plates the day before transfection. Attractene (Qiagen) was used for transfection according to the manufacturer&#x02019;s protocol. Ater 24 h of incubation, the cells were subjected to different treatments. pcDNA3 empty vectors were used as controls for transfection experiments.</p></sec>
<sec>
<title>Isolation of cytosolic protein fractions</title>
<p>Cells were seeded in 6-well culture plates at 40&#x02013;50&#x00025; confluence. The next day, the cells were incubated with a determined dose of Sal B. Then, the cells were trypsinized, washed twice with ice-cold PBS, and the cytosolic protein fractions were isolated using the Cell Mitochondria Isolation kit (Beyotime) according to the manufacturer&#x02019;s protocol.</p></sec>
<sec>
<title>Western blot analysis</title>
<p>Western blot analysis was performed as described previously (<xref rid="b19-ijo-49-06-2538" ref-type="bibr">19</xref>). Briely, proteins (40 &#x003BC;g) were resolved by 6&#x02013;15&#x00025; sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to polyvinylidene diluoride membranes (Millipore, Billerica, MA, USA). The membranes were then blocked in 5&#x00025; (w/v) skimmed-milk for 1 h, followed by incubation with appropriate primary antibodies (diluted 1:1,000&#x02013;1:5,000) overnight at 4&#x000B0;C. Bound antibodies were detected with peroxidase-conjugated goat anti-rabbit or goat anti-mouse secondary antibodies and the blots developed using enhanced chemiluminescence (Millipore). Western blot analysis data were quantified by ImageJ densitometric analysis and normalized by GAPDH.</p></sec>
<sec>
<title>Statistical analysis</title>
<p>All experiments were performed at least three times, and the data were presented as the mean &#x000B1; standard deviation. GraphPad Prism 5.0 was used for statistical analysis. A difference was considered significant at P&lt;0.05.</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>Sal B inhibits growth of HCC cells</title>
<p>We first examined the inhibitory effect of Sal B on viability in HCC cell lines. As shown in <xref rid="f1-ijo-49-06-2538" ref-type="fig">Fig. 1A</xref>, Sal B significantly inhibited the growth of cancer cells in a dose-dependent manner, with a half maximal inhibitory concentration (IC<sub>50</sub>) of 143.82 &#x003BC;M for SK-Hep-1 and 240.11 &#x003BC;M for Bel-7404 after 48 h of exposure. Colony-formation experiments also indicated that Sal B markedly inhibited the growth of HCC cells (<xref rid="f1-ijo-49-06-2538" ref-type="fig">Fig. 1B and C</xref>). We also investigated the effects of Sal B on the growth of HL-7702 cells (a normal human liver cell line). The results showed that the cytotoxic effect of Sal B on HL-7702 cells (IC<sub>50</sub> 758.63 &#x003BC;M) appeared much lower than that observed in SK-Hep-1 and Bel-7404 cells (<xref rid="f1-ijo-49-06-2538" ref-type="fig">Fig. 1D</xref>).</p></sec>
<sec>
<title>Sal B induces apoptotic cell death in HCC cells</title>
<p>To examine the cell growth inhibition induced by Sal B related to apoptosis, Sal B-treated cells were stained with propidium iodide (PI)/Annexin V-FITC and quantified by flow cytometry. The quantification shown for apoptosis reflected the values for total apoptosis. We also determined whether apoptosis was dose- or time-dependent altered in cells treated with Sal B. Sal B induced a dose- and time-dependent increase of apoptosis in HCC cells (<xref rid="f2-ijo-49-06-2538" ref-type="fig">Fig. 2A&#x02013;C</xref>).</p>
<p>Then we measured the mitochondrial membrane potential (&#x00394;&#x003A8;m) by flow cytometry and found that Sal B treatment led to depolarization of &#x00394;&#x003A8;m in a dose-dependent manner (<xref rid="f2-ijo-49-06-2538" ref-type="fig">Fig. 2D</xref>). Western blot analyses showed that cleaved caspase-9, cleaved caspase-3, cleaved poly(ADP-ribose) polymerase (PARP), and cytosolic Cyto c were increased after treatment with Sal B for 24 h (<xref rid="f2-ijo-49-06-2538" ref-type="fig">Fig. 2E</xref>). The level of cleaved PARP, cleaved caspase-3, cleaved caspase-9, and cytosolic Cyto c increased 2.8-, 3.0-, 2.9- and 2.5-fold, respectively, in SK-Hep-1 cells treated with 200 &#x003BC;M Sal B for 24 h (<xref rid="f2-ijo-49-06-2538" ref-type="fig">Fig. 2E</xref>). The level of cleaved PARP, cleaved caspase-3, cleaved caspase-9, and cytosolic Cyto c increased 3.4-, 2.7-, 2.4- and 2.8-fold, respectively, in Bel-7404 cells treated with 200 &#x003BC;M Sal B for 24 h (<xref rid="f2-ijo-49-06-2538" ref-type="fig">Fig. 2E</xref>). These results demonstrated that Sal B induced apoptosis in the HCC cells.</p></sec>
<sec>
<title>Sal B induces autophagy in HCC cells</title>
<p>Apoptosis and autophagy are highly interactive. To examine whether Sal B could induce autophagy, the treated cells were analyzed by western blot analysis and electron microscopy. The characteristics of autophagosomes are described as double-layer structure with cytoplasmic components. After treatment with Sal B for 24 h, most of the HCC cells displayed an extensive accumulation of double structures with a broad range of morphologies, indicating the formation of autophagosomes (<xref rid="f3-ijo-49-06-2538" ref-type="fig">Fig. 3</xref>). The significantly increased expression of LC3-II, Beclin-1 and the attenuated expression of p62/SQSTM1 were observed in cells treat with Sal B for 24 h (<xref rid="f4-ijo-49-06-2538" ref-type="fig">Fig. 4A</xref>). The level of LC3-II and Beclin-1 increased 3.1- and 2.3-fold, while the level of p62 decreased 80&#x00025;, in SK-Hep-1 cells treated with 200 &#x003BC;M Sal B for 24 h (<xref rid="f4-ijo-49-06-2538" ref-type="fig">Fig. 4A</xref>). The level of LC3-II and Beclin-1 increased 3.5- and 2.6-fold, respectively, while the level of p62 decreased 70&#x00025;, in Bel-7404 cells treated with 200 &#x003BC;M Sal B for 24 h (<xref rid="f4-ijo-49-06-2538" ref-type="fig">Fig. 4A</xref>).</p>
<p>For further confirmation, the cells were incubated with an antibody against microtubule-associated protein 1 light chain 3 (LC3). The punctate LC3 II-labeled autophagolysosome vacuoles were frequently observed in cells treated with Sal B for 48 h compared with their controls (<xref rid="f4-ijo-49-06-2538" ref-type="fig">Fig. 4B</xref>). Next, we determined whether autophagy was time-dependently altered in cells treated with Sal B. A time-dependent increase of punctate LC3-II dots was observed from 12-, 24- and 48-h in cells treated with Sal B (<xref rid="f4-ijo-49-06-2538" ref-type="fig">Fig. 4C</xref>).</p></sec>
<sec>
<title>Interactions between Sal B-induced autophagy and apoptotic cell death in HCC cells</title>
<p>The relationships between autophagy and apoptosis are complicated. There is consensus that the relationships between autophagy and apoptosis are highly depended on the tumor types and stimulus characteristic. To confirm the role of Sal B-induced autophagy in HCC cells promoted or inhibited apoptosis, we treated the cells with the autophagy inhibitor 3-MA and CQ. Addition of 5 mM 3-MA or 5 &#x003BC;M CQ attenuated Sal B-induced apoptosis in HCC cells (<xref rid="f5-ijo-49-06-2538" ref-type="fig">Fig. 5A</xref>). In addition, siRNAs against Beclin-1 was used to block autophagy. The level of Beclin-1 decreased 70&#x00025; in SK-Hep-1 cells and 60&#x00025; in Bel-7404 cells treated with siRNAs against Beclin-1 (<xref rid="f5-ijo-49-06-2538" ref-type="fig">Fig. 5B</xref>). Inhibition of autophagy attenuated Sal B-induced apoptosis in HCC cells (<xref rid="f5-ijo-49-06-2538" ref-type="fig">Fig. 5B</xref>).</p>
<p>Western blot analysis was used to detect the influence of 3-MA pretreatment on cleaved PARP and cleaved caspase-3 expression induced by Sal B. Autophagy level was found to significantly decrease after 3-MA pretreatment, and the expressions of cleaved PARP and cleaved caspase-3 also decreased (<xref rid="f5-ijo-49-06-2538" ref-type="fig">Fig. 5C</xref>). The level of cleaved PARP, cleaved caspase-3, and LC3-II decreased from 4.5- to 2.1-, 2.7- to 1.9- and 5.5- to 1.6-fold, respectively, in SK-Hep-1 cells treated with 200 &#x003BC;M Sal B and the combination of Sal B and 3-MA for 24 h (<xref rid="f5-ijo-49-06-2538" ref-type="fig">Fig. 5C</xref>). The level of cleaved PARP, cleaved caspase-3, and LC3-II decreased from 3.4- to 2.5-, 3.1- to 2.2- and 4.2-to 1.2-fold, respectively, in Bel-7404 cells treated with 200 &#x003BC;M Sal B and the combination of Sal B and 3-MA for 24 h (<xref rid="f5-ijo-49-06-2538" ref-type="fig">Fig. 5C</xref>). All the results demonstrated that the inhibition of autophagy in HCC cells had the potential of attenuating Sal B-induced apoptosis.</p></sec>
<sec>
<title>AKT/mTOR signaling pathway is involved in Sal B-induced autophagy in HCC cells</title>
<p>AKT/mTOR signaling pathway is the key regulatory molecule of both autophagy and apoptosis. Therefore, we investigated whether the AKT/mTOR pathway played a central role in Sal B-mediated cell death. Western blot analysis confirmed that the levels of phosphorylated AKT, mTOR and its downstream effector p70S6K and p-4EBP1 were significantly reduced by Sal B (<xref rid="f6-ijo-49-06-2538" ref-type="fig">Fig. 6A</xref>). The level of phosphorylated AKT, mTOR, p70S6K and p-4EBP1 decreased 70, 70, 70 and 60&#x00025;, respectively, in SK-Hep-1 cells treated with 200 &#x003BC;M Sal B for 24 h (<xref rid="f6-ijo-49-06-2538" ref-type="fig">Fig. 6A</xref>). The level of phosphorylated AKT, mTOR, p70S6K and p-4EBP1 decreased 70, 80, 70 and 70&#x00025;, respectively, in Bel-7404 cells treated with 200 &#x003BC;M Sal B for 24 h (<xref rid="f6-ijo-49-06-2538" ref-type="fig">Fig. 6A</xref>).</p>
<p>To further identify the role of AKT in Sal B-induced biological effects, HCC cells were transiently transfected with pcDNA3-AKT-T7 plasmid. The level of phosphorylated AKT and total AKT increased 2.0- and 5.5-fold in SK-Hep-1 cells, while 1.6- and 5.2-fold in Bel-7404 cells transfected with pcDNA3-AKT-T7 plasmid (<xref rid="f6-ijo-49-06-2538" ref-type="fig">Fig. 6D</xref>). As shown in <xref rid="f6-ijo-49-06-2538" ref-type="fig">Fig. 6B&#x02013;D</xref>, enforced expression of AKT significantly attenuated Sal B-induced growth inhibition, and apoptosis. Furthermore, Sal B-induced autophagy was also decreased in the transfected cells (<xref rid="f6-ijo-49-06-2538" ref-type="fig">Figs. 6D</xref> and <xref rid="f7-ijo-49-06-2538" ref-type="fig">7</xref>). The level of cleaved PARP and LC3-II decreased from 2.6- to 1.4- and 2.2- to 1.3-fold, respectively, in SK-Hep-1 cells treated with 200 &#x003BC;M Sal B and the combination of Sal B and pcDNA3-AKT (<xref rid="f6-ijo-49-06-2538" ref-type="fig">Fig. 6D</xref>). The level of cleaved PARP and LC3-II decreased from 2.7- to 1.5- and 1.8- to 1.2-fold, respectively, in Bel-7404 cells treated with 200 &#x003BC;M Sal B and the combination of Sal B and pcDNA3-AKT (<xref rid="f6-ijo-49-06-2538" ref-type="fig">Fig. 6D</xref>). These results suggested that overexpression of AKT can override the Sal B-induced biological effects in HCC cells. Taken together, these data demonstrate that AKT is a critical mediator in regulating Sal B-mediated biological effects.</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Currently, the prognosis of HCC is poor even with multidisciplinary comprehensive treatment, and recurrence rate is &gt;50&#x00025; (<xref rid="b20-ijo-49-06-2538" ref-type="bibr">20</xref>,<xref rid="b21-ijo-49-06-2538" ref-type="bibr">21</xref>). There is an urgent need for development of efficacious therapies. Growing evidence indicates that Chinese medicine plays a promising role in developing novel anticancer drugs. Understanding the anti-neoplastic mechanisms of Chinese medicine may help improve the efficacy of these agents.</p>
<p>In this study, we demonstrated that Sal B markedly inhibited the proliferation of HCC cells. We also showed that Sal B induced mitochondria-mediated apoptosis in HCC cells, accompanied by a decrease of mitochondrial potential, and increase of cytosol cytochrome <italic>c</italic>. Release of cytochrome <italic>c</italic> from the mitochondria into cytosol activates intrinsic apoptosis (<xref rid="b22-ijo-49-06-2538" ref-type="bibr">22</xref>). Cytosolic Cyto c initiates the apoptotic process by activating a downstream cascade of caspases through processing of procaspase-9 (<xref rid="b23-ijo-49-06-2538" ref-type="bibr">23</xref>). In accord with our findings, some researchers reported that Sal B inhibited the growth of cancer cells through induction of apoptosis (<xref rid="b24-ijo-49-06-2538" ref-type="bibr">24</xref>,<xref rid="b25-ijo-49-06-2538" ref-type="bibr">25</xref>).</p>
<p>Both apoptosis and autophagy are crucial mechanisms regulating cell survival (<xref rid="b26-ijo-49-06-2538" ref-type="bibr">26</xref>). We thus examined whether Sal B induced autophagy. Autophagy is a tightly regulated intracellular self-digestive process involving the lysosomal degradation of cytoplasmic organelles and proteins (<xref rid="b27-ijo-49-06-2538" ref-type="bibr">27</xref>,<xref rid="b28-ijo-49-06-2538" ref-type="bibr">28</xref>). In this process, cells digest their own cellular contents by lysosomal degradation and recycle the ingredients to maintain cell survival (<xref rid="b29-ijo-49-06-2538" ref-type="bibr">29</xref>&#x02013;<xref rid="b31-ijo-49-06-2538" ref-type="bibr">31</xref>). Our data revealed that Sal B could induce autophagy accompanied by apoptosis in HCC cells. Apoptosis and autophagy could be induced by the same stimulus, but the interaction between them was still unclear. In our study, we found that suppression of autophagy by pharmacological inhibitors (3-MA and CQ) or Beclin-1 siRNA decreased Sal B-induced apoptosis in HCC cells, revealing that the autophagy induced by Sal B promoted HCC cell apoptosis. These results were consistent with the findings of Kim <italic>et al</italic> (<xref rid="b32-ijo-49-06-2538" ref-type="bibr">32</xref>), who reported that the inhibition of autophagy decreased docosahexaenoic acid-induced apoptosis in non-small cell lung cancer cells, indicating that autophagy was a prerequisite for apoptotic cell death. Autophagy can inhibit, delay or promote apoptosis (<xref rid="b33-ijo-49-06-2538" ref-type="bibr">33</xref>&#x02013;<xref rid="b35-ijo-49-06-2538" ref-type="bibr">35</xref>). The mechansims of autophagy promoting apoptosis may include upregulation of cells susceptible to drug-induced apoptosis and activating of caspases (<xref rid="b36-ijo-49-06-2538" ref-type="bibr">36</xref>,<xref rid="b37-ijo-49-06-2538" ref-type="bibr">37</xref>). In this study, our data showed that apoptosis level was significantly increased with upregulation of autophagy level. We hypothesize that Sal B could trigger apoptosis and autophagy simultaneously, whereas autophagy increased HCC cells susceptible to Sal B-induced apoptosis. Inhibition of autophagy could significantly reduce the extent of Sal B-induced apoptosis. The interaction between autophagy and apoptosis is extremely complex and needs further investigation.</p>
<p>The molecular mechanism mediating apoptosis and autophagy are complicated. Increasing evidence indicates that autophagy and apoptosis share many common regulatory molecules, such as AKT/mTOR signaling pathway (<xref rid="b38-ijo-49-06-2538" ref-type="bibr">38</xref>). It is well known that the AKT/mTOR pathway plays an important role in cell growth, survival, differentiation and metabolism (<xref rid="b39-ijo-49-06-2538" ref-type="bibr">39</xref>). The aberrant activation of AKT/mTOR signaling pathway contributes to a poor prognosis and plays a critical role in carcinogenesis of HCC (<xref rid="b40-ijo-49-06-2538" ref-type="bibr">40</xref>). Inhibition of AKT/mTOR signaling pathway causes cell death associated with apoptosis and autophagy (<xref rid="b41-ijo-49-06-2538" ref-type="bibr">41</xref>). The downstream target of Akt/mTOR pathway can potently block Bad-induced apoptosis by phosphorylation of Bad at S136 site to disrupt Bad&#x02019;s binding to Bcl-XL and/or Bcl-2. Thus, inhibition of Akt/mTOR pathway possibly increases apoptosis (<xref rid="b42-ijo-49-06-2538" ref-type="bibr">42</xref>).</p>
<p>Our results show that Sal B treatment decreases AKT/mTOR pathway activity. This inhibitory effect was correlated with the decrease of phosphorylation of AKT, mTOR and their downstream targets, p70S6K and 4E-BP1. Overexpression of AKT abolished the effects of Sal B on HCC cells. These findings indicate that Sal B induces apoptosis and autophagy in HCC cells through inhibition of the AKT/mTOR signaling pathway. Moreover, the appearance of apoptosis and autophagy after Sal B treatment is closely linked to the inhibition of AKT/mTOR pathway, demonstrating this pathway plays a pivotal role in HCC treatment.</p>
<p>In conclusion, our results demonstrate for the first time that Sal B suppressed cell proliferation and induces autophagy and apoptosis in HCC cells through the AKT/mTOR pathway. Sal B could act as a new anticancer agent for HCC by inducing apoptosis and autophagy. These results will expand our knowledge of the anticancer molecular mechanisms of Sal B and the interaction between autophagy and apoptosis.</p></sec></body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This study was supported by the grants from Medical Health Research Project of Zhejiang province (2015KYB301); Science and Technology Planning Project of Hangzhou (20150733Q20); Health Science and Technology Plan Projects of Hangzhou (2014A11); Science and Technology Planning Project of Wenzhou (2015Y0395).</p></ack>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term id="G1">CQ</term>
<def>
<p>chloroquine</p></def></def-item>
<def-item>
<term id="G2">Cyto c</term>
<def>
<p>cytochrome <italic>c</italic></p></def></def-item>
<def-item>
<term id="G3">HCC</term>
<def>
<p>hepatocellular carcinoma</p></def></def-item>
<def-item>
<term id="G4">LC3</term>
<def>
<p>microtubule-associated protein 1 light chain 3</p></def></def-item>
<def-item>
<term id="G5">PARP</term>
<def>
<p>poly(ADP-ribose) polymerase</p></def></def-item>
<def-item>
<term id="G6">PI</term>
<def>
<p>propidium iodide</p></def></def-item>
<def-item>
<term id="G7">PVDF</term>
<def>
<p>polyvinyldifluoride</p></def></def-item>
<def-item>
<term id="G8">SDS-PAGE</term>
<def>
<p>sodium dodecyl sulfate polyacrylamide gel electrophoresis</p></def></def-item>
<def-item>
<term id="G9">&#x00394;&#x003A8;m</term>
<def>
<p>membrane potential</p></def></def-item>
<def-item>
<term id="G10">3-MA</term>
<def>
<p>3-methyladenine</p></def></def-item></def-list></glossary>
<ref-list>
<title>References</title>
<ref id="b1-ijo-49-06-2538"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fares</surname><given-names>N</given-names></name><name><surname>Peron</surname><given-names>JM</given-names></name></person-group><article-title>Epidemiology, natural history, and risk factors of hepatocellular carcinoma</article-title><source>Rev Prat</source><volume>63</volume><fpage>216</fpage><lpage>217</lpage><fpage>220</fpage><lpage>212</lpage><year>2013</year><comment>(In French)</comment></element-citation></ref>
<ref id="b2-ijo-49-06-2538"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Lortet-Tieulent</surname><given-names>J</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics, 2012</article-title><source>CA Cancer J Clin</source><volume>65</volume><fpage>87</fpage><lpage>108</lpage><year>2015</year><pub-id pub-id-type="doi">10.3322/caac.21262</pub-id><pub-id pub-id-type="pmid">25651787</pub-id></element-citation></ref>
<ref id="b3-ijo-49-06-2538"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karaman</surname><given-names>B</given-names></name><name><surname>Battal</surname><given-names>B</given-names></name><name><surname>Sari</surname><given-names>S</given-names></name><name><surname>Verim</surname><given-names>S</given-names></name></person-group><article-title>Hepatocellular carcinoma review: Current treatment, and evidence-based medicine</article-title><source>World J Gastroenterol</source><volume>20</volume><fpage>18059</fpage><lpage>18060</lpage><year>2014</year><pub-id pub-id-type="pmid">25548509</pub-id><pub-id pub-id-type="pmcid">4273161</pub-id></element-citation></ref>
<ref id="b4-ijo-49-06-2538"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhm</surname><given-names>JE</given-names></name><name><surname>Park</surname><given-names>JO</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Yoo</surname><given-names>BC</given-names></name><name><surname>Paik</surname><given-names>SW</given-names></name><name><surname>Koh</surname><given-names>KC</given-names></name><name><surname>Kang</surname><given-names>WK</given-names></name><name><surname>Lim</surname><given-names>HY</given-names></name></person-group><article-title>A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma</article-title><source>Cancer Chemother Pharmacol</source><volume>63</volume><fpage>929</fpage><lpage>935</lpage><year>2009</year><pub-id pub-id-type="doi">10.1007/s00280-008-0817-4</pub-id></element-citation></ref>
<ref id="b5-ijo-49-06-2538"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name></person-group><article-title>Systemic therapies for hepatocellular carcinoma</article-title><source>Drug Discov Ther</source><volume>9</volume><fpage>352</fpage><lpage>362</lpage><year>2015</year><pub-id pub-id-type="doi">10.5582/ddt.2015.01047</pub-id><pub-id pub-id-type="pmid">26632544</pub-id></element-citation></ref>
<ref id="b6-ijo-49-06-2538"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>EL</given-names></name><name><surname>Yeon</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Suh</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Kang</surname><given-names>SH</given-names></name><name><surname>Kang</surname><given-names>K</given-names></name><name><surname>Yoo</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Yim</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability</article-title><source>J Clin Gastroenterol</source><volume>48</volume><fpage>e22</fpage><lpage>e29</lpage><year>2014</year><pub-id pub-id-type="doi">10.1097/MCG.0b013e3182a54ec8</pub-id></element-citation></ref>
<ref id="b7-ijo-49-06-2538"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Ricci</surname><given-names>S</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Hilgard</surname><given-names>P</given-names></name><name><surname>Gane</surname><given-names>E</given-names></name><name><surname>Blanc</surname><given-names>JF</given-names></name><name><surname>de Oliveira</surname><given-names>AC</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Raoul</surname><given-names>JL</given-names></name><name><surname>Forner</surname><given-names>A</given-names></name><etal/></person-group><collab>SHARP Investigators Study Group</collab><article-title>Sorafenib in advanced hepatocellular carcinoma</article-title><source>N Engl J Med</source><volume>359</volume><fpage>378</fpage><lpage>390</lpage><year>2008</year><pub-id pub-id-type="doi">10.1056/NEJMoa0708857</pub-id><pub-id pub-id-type="pmid">18650514</pub-id></element-citation></ref>
<ref id="b8-ijo-49-06-2538"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>LT</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>FH</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Mo</surname><given-names>GY</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name></person-group><article-title>Triterpenoid saponin flaccidoside II from Anemone flaccida triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors via the MAPK-HO-1 pathway</article-title><source>Onco Targets Ther</source><volume>9</volume><fpage>1969</fpage><lpage>1979</lpage><year>2016</year><pub-id pub-id-type="pmid">27103823</pub-id><pub-id pub-id-type="pmcid">4827896</pub-id></element-citation></ref>
<ref id="b9-ijo-49-06-2538"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>Synergistic effect and molecular mechanisms of traditional Chinese medicine on regulating tumor microenvironment and cancer cells</article-title><source>BioMed Res Int</source><volume>2016</volume><fpage>1490738</fpage><year>2016</year><pub-id pub-id-type="doi">10.1155/2016/1490738</pub-id><pub-id pub-id-type="pmid">27042656</pub-id><pub-id pub-id-type="pmcid">4793102</pub-id></element-citation></ref>
<ref id="b10-ijo-49-06-2538"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>M</given-names></name><name><surname>Zhong</surname><given-names>LX</given-names></name><name><surname>Zhan</surname><given-names>ZY</given-names></name><name><surname>Huang</surname><given-names>ZH</given-names></name><name><surname>Xiong</surname><given-names>JP</given-names></name></person-group><article-title>Resveratrol treatment inhibits proliferation of and induces apoptosis in human colon cancer cells</article-title><source>Med Sci Monit</source><volume>22</volume><fpage>1101</fpage><lpage>1108</lpage><year>2016</year><pub-id pub-id-type="doi">10.12659/MSM.897905</pub-id><pub-id pub-id-type="pmid">27040803</pub-id><pub-id pub-id-type="pmcid">4822945</pub-id></element-citation></ref>
<ref id="b11-ijo-49-06-2538"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Bang</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>HW</given-names></name><name><surname>Sung</surname><given-names>SH</given-names></name><name><surname>Han</surname><given-names>JS</given-names></name><name><surname>Jeon</surname><given-names>WK</given-names></name></person-group><article-title>Salvia miltiorrhiza extract protects white matter and the hippocampus from damage induced by chronic cerebral hypoperfusion in rats</article-title><source>BMC Complement Altern Med</source><volume>15</volume><fpage>415</fpage><year>2015</year><pub-id pub-id-type="doi">10.1186/s12906-015-0943-6</pub-id><pub-id pub-id-type="pmid">26597908</pub-id><pub-id pub-id-type="pmcid">4657337</pub-id></element-citation></ref>
<ref id="b12-ijo-49-06-2538"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name></person-group><article-title>Optimization of extraction and antioxidant activity of polysaccharides from Salvia miltiorrhiza Bunge residue</article-title><source>Int J Biol Macromol</source><volume>79</volume><fpage>533</fpage><lpage>541</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2015.05.024</pub-id><pub-id pub-id-type="pmid">26014144</pub-id></element-citation></ref>
<ref id="b13-ijo-49-06-2538"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Cheung</surname><given-names>CM</given-names></name><name><surname>Yang</surname><given-names>JM</given-names></name><name><surname>Or</surname><given-names>PM</given-names></name><name><surname>Lee</surname><given-names>WY</given-names></name><name><surname>Yeung</surname><given-names>JH</given-names></name></person-group><article-title>Danshen (Salvia miltiorrhiza) water extract inhibits paracetamol-induced toxicity in primary rat hepatocytes via reducing CYP2E1 activity and oxidative stress</article-title><source>J Pharm Pharmacol</source><volume>67</volume><fpage>980</fpage><lpage>989</lpage><year>2015</year><pub-id pub-id-type="doi">10.1111/jphp.12381</pub-id><pub-id pub-id-type="pmid">25645193</pub-id></element-citation></ref>
<ref id="b14-ijo-49-06-2538"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Chu</surname><given-names>K</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name></person-group><article-title>Biological activities of salvianolic acid B from Salvia miltiorrhiza on type 2 diabetes induced by high-fat diet and streptozotocin</article-title><source>Pharm Biol</source><volume>53</volume><fpage>1058</fpage><lpage>1065</lpage><year>2015</year><pub-id pub-id-type="doi">10.3109/13880209.2014.959611</pub-id><pub-id pub-id-type="pmid">25612777</pub-id></element-citation></ref>
<ref id="b15-ijo-49-06-2538"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>ZS</given-names></name><name><surname>Luo</surname><given-names>P</given-names></name><name><surname>Dai</surname><given-names>SH</given-names></name><name><surname>Liu</surname><given-names>ZB</given-names></name><name><surname>Zheng</surname><given-names>XR</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name></person-group><article-title>Salvianolic acid B induces apoptosis in human glioma U87 cells through p38-mediated ROS generation</article-title><source>Cell Mol Neurobiol</source><volume>33</volume><fpage>921</fpage><lpage>928</lpage><year>2013</year><pub-id pub-id-type="doi">10.1007/s10571-013-9958-z</pub-id><pub-id pub-id-type="pmid">23842993</pub-id></element-citation></ref>
<ref id="b16-ijo-49-06-2538"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Ge</surname><given-names>PJ</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>FL</given-names></name><name><surname>Zhu</surname><given-names>QY</given-names></name></person-group><article-title>Modulation of growth and angiogenic potential of oral squamous carcinoma cells in vitro using salvianolic acid B</article-title><source>BMC Complement Altern Med</source><volume>11</volume><fpage>54</fpage><year>2011</year><pub-id pub-id-type="doi">10.1186/1472-6882-11-54</pub-id><pub-id pub-id-type="pmid">21726465</pub-id><pub-id pub-id-type="pmcid">3158556</pub-id></element-citation></ref>
<ref id="b17-ijo-49-06-2538"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>QL</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Tao</surname><given-names>YY</given-names></name><name><surname>Liu</surname><given-names>CH</given-names></name><name><surname>El-Nezami</surname><given-names>H</given-names></name></person-group><article-title>Salvianolic acid B modulates the expression of drug-metabolizing enzymes in HepG2 cells</article-title><source>Hepatobiliary Pancreat Dis Int</source><volume>10</volume><fpage>502</fpage><lpage>508</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/S1499-3872(11)60085-4</pub-id><pub-id pub-id-type="pmid">21947724</pub-id></element-citation></ref>
<ref id="b18-ijo-49-06-2538"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Kuai</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Jing</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cardioprotective effect of salvianolic acid B on acute myocardial infarction by promoting autophagy and neovascularization and inhibiting apoptosis</article-title><source>J Pharm Pharmacol</source><volume>68</volume><fpage>941</fpage><lpage>952</lpage><year>2016</year><pub-id pub-id-type="doi">10.1111/jphp.12567</pub-id><pub-id pub-id-type="pmid">27139338</pub-id></element-citation></ref>
<ref id="b19-ijo-49-06-2538"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JY</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>MY</given-names></name><name><surname>Wang</surname><given-names>YS</given-names></name><name><surname>Hou</surname><given-names>MF</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Krishna</surname><given-names>N</given-names></name><name><surname>Chiu</surname><given-names>SJ</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><etal/></person-group><article-title>STIM1 overexpression promotes colorectal cancer progression, cell motility and COX-2 expression</article-title><source>Oncogene</source><volume>34</volume><fpage>4358</fpage><lpage>4367</lpage><year>2015</year><pub-id pub-id-type="doi">10.1038/onc.2014.366</pub-id><pub-id pub-id-type="pmcid">4426254</pub-id></element-citation></ref>
<ref id="b20-ijo-49-06-2538"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tagliamonte</surname><given-names>M</given-names></name><name><surname>Petrizzo</surname><given-names>A</given-names></name><name><surname>Tornesello</surname><given-names>ML</given-names></name><name><surname>Ciliberto</surname><given-names>G</given-names></name><name><surname>Buonaguro</surname><given-names>FM</given-names></name><name><surname>Buonaguro</surname><given-names>L</given-names></name></person-group><article-title>Combinatorial immunotherapy strategies for hepatocellular carcinoma</article-title><source>Curr Opin Immunol</source><volume>39</volume><fpage>103</fpage><lpage>113</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.coi.2016.01.005</pub-id><pub-id pub-id-type="pmid">26851637</pub-id></element-citation></ref>
<ref id="b21-ijo-49-06-2538"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Heo</surname><given-names>MK</given-names></name><name><surname>Song</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Yi</surname><given-names>NJ</given-names></name><name><surname>Lee</surname><given-names>KW</given-names></name><name><surname>Suh</surname><given-names>KS</given-names></name><etal/></person-group><article-title>A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma</article-title><source>Br J Cancer</source><volume>113</volume><fpage>1666</fpage><lpage>1676</lpage><year>2015</year><pub-id pub-id-type="doi">10.1038/bjc.2015.430</pub-id><pub-id pub-id-type="pmid">26657650</pub-id><pub-id pub-id-type="pmcid">4702003</pub-id></element-citation></ref>
<ref id="b22-ijo-49-06-2538"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babbitt</surname><given-names>SE</given-names></name><name><surname>Sutherland</surname><given-names>MC</given-names></name><name><surname>San Francisco</surname><given-names>B</given-names></name><name><surname>Mendez</surname><given-names>DL</given-names></name><name><surname>Kranz</surname><given-names>RG</given-names></name></person-group><article-title>Mitochondrial cytochrome c biogenesis: No longer an enigma</article-title><source>Trends Biochem Sci</source><volume>40</volume><fpage>446</fpage><lpage>455</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.tibs.2015.05.006</pub-id><pub-id pub-id-type="pmid">26073510</pub-id><pub-id pub-id-type="pmcid">4509832</pub-id></element-citation></ref>
<ref id="b23-ijo-49-06-2538"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulikov</surname><given-names>AV</given-names></name><name><surname>Shilov</surname><given-names>ES</given-names></name><name><surname>Mufazalov</surname><given-names>IA</given-names></name><name><surname>Gogvadze</surname><given-names>V</given-names></name><name><surname>Nedospasov</surname><given-names>SA</given-names></name><name><surname>Zhivotovsky</surname><given-names>B</given-names></name></person-group><article-title>Cytochrome c: The Achilles&#x02019; heel in apoptosis</article-title><source>Cell Mol Life Sci</source><volume>69</volume><fpage>1787</fpage><lpage>1797</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/s00018-011-0895-z</pub-id></element-citation></ref>
<ref id="b24-ijo-49-06-2538"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>T</given-names></name><name><surname>Korotcov</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Pang</surname><given-names>X</given-names></name><name><surname>Shan</surname><given-names>L</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Sridhar</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Califano</surname><given-names>J</given-names></name><etal/></person-group><article-title>Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways</article-title><source>Int J Cancer</source><volume>124</volume><fpage>2200</fpage><lpage>2209</lpage><year>2009</year><pub-id pub-id-type="doi">10.1002/ijc.24160</pub-id><pub-id pub-id-type="pmid">19123475</pub-id><pub-id pub-id-type="pmcid">2849633</pub-id></element-citation></ref>
<ref id="b25-ijo-49-06-2538"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name></person-group><article-title>Salvianolic acid B, a potential chemopreventive agent, for head and neck squamous cell cancer</article-title><source>J Oncol</source><volume>2011</volume><fpage>534548</fpage><year>2011</year><pub-id pub-id-type="doi">10.1155/2011/534548</pub-id><pub-id pub-id-type="pmid">21209716</pub-id><pub-id pub-id-type="pmcid">3010684</pub-id></element-citation></ref>
<ref id="b26-ijo-49-06-2538"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryter</surname><given-names>SW</given-names></name><name><surname>Mizumura</surname><given-names>K</given-names></name><name><surname>Choi</surname><given-names>AM</given-names></name></person-group><article-title>The impact of autophagy on cell death modalities</article-title><source>Int J Cell Biol</source><volume>2014</volume><fpage>502676</fpage><year>2014</year><pub-id pub-id-type="doi">10.1155/2014/502676</pub-id><pub-id pub-id-type="pmid">24639873</pub-id><pub-id pub-id-type="pmcid">3932252</pub-id></element-citation></ref>
<ref id="b27-ijo-49-06-2538"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>B</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Autophagy in the pathogenesis of disease</article-title><source>Cell</source><volume>132</volume><fpage>27</fpage><lpage>42</lpage><year>2008</year><pub-id pub-id-type="doi">10.1016/j.cell.2007.12.018</pub-id><pub-id pub-id-type="pmid">18191218</pub-id><pub-id pub-id-type="pmcid">2696814</pub-id></element-citation></ref>
<ref id="b28-ijo-49-06-2538"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>B</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Autophagy in aging, disease and death: The true identity of a cell death impostor</article-title><source>Cell Death Differ</source><volume>16</volume><fpage>1</fpage><lpage>2</lpage><year>2009</year><pub-id pub-id-type="doi">10.1038/cdd.2008.139</pub-id><pub-id pub-id-type="pmcid">2717606</pub-id></element-citation></ref>
<ref id="b29-ijo-49-06-2538"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eskelinen</surname><given-names>EL</given-names></name><name><surname>Saftig</surname><given-names>P</given-names></name></person-group><article-title>Autophagy: A lysosomal degradation pathway with a central role in health and disease</article-title><source>Biochim Biophys Acta</source><volume>1793</volume><fpage>664</fpage><lpage>673</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.bbamcr.2008.07.014</pub-id></element-citation></ref>
<ref id="b30-ijo-49-06-2538"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Klionsky</surname><given-names>DJ</given-names></name></person-group><article-title>Eaten alive: A history of macroautophagy</article-title><source>Nat Cell Biol</source><volume>12</volume><fpage>814</fpage><lpage>822</lpage><year>2010</year><pub-id pub-id-type="doi">10.1038/ncb0910-814</pub-id><pub-id pub-id-type="pmid">20811353</pub-id><pub-id pub-id-type="pmcid">3616322</pub-id></element-citation></ref>
<ref id="b31-ijo-49-06-2538"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizushima</surname><given-names>N</given-names></name><name><surname>Levine</surname><given-names>B</given-names></name><name><surname>Cuervo</surname><given-names>AM</given-names></name><name><surname>Klionsky</surname><given-names>DJ</given-names></name></person-group><article-title>Autophagy fights disease through cellular self-digestion</article-title><source>Nature</source><volume>451</volume><fpage>1069</fpage><lpage>1075</lpage><year>2008</year><pub-id pub-id-type="doi">10.1038/nature06639</pub-id><pub-id pub-id-type="pmid">18305538</pub-id><pub-id pub-id-type="pmcid">2670399</pub-id></element-citation></ref>
<ref id="b32-ijo-49-06-2538"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>Jeong</surname><given-names>S</given-names></name><name><surname>Jing</surname><given-names>K</given-names></name><name><surname>Shin</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Heo</surname><given-names>JY</given-names></name><name><surname>Kweon</surname><given-names>GR</given-names></name><name><surname>Park</surname><given-names>SK</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Park</surname><given-names>JI</given-names></name><etal/></person-group><article-title>Docosahexaenoic acid induces cell death in human non-small cell lung cancer cells by repressing mTOR via AMPK activation and PI3K/Akt inhibition</article-title><source>BioMed Res Int</source><volume>2015</volume><fpage>239764</fpage><year>2015</year><pub-id pub-id-type="doi">10.1155/2015/239764</pub-id><pub-id pub-id-type="pmid">26339598</pub-id><pub-id pub-id-type="pmcid">4538321</pub-id></element-citation></ref>
<ref id="b33-ijo-49-06-2538"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>WR</given-names></name><name><surname>Chen</surname><given-names>YL</given-names></name><name><surname>Hsu</surname><given-names>HC</given-names></name><name><surname>Chen</surname><given-names>WJ</given-names></name></person-group><article-title>Antimicrobial peptide GW-H1-induced apoptosis of human gastric cancer AGS cell line is enhanced by suppression of autophagy</article-title><source>Mol Cell Biochem</source><volume>400</volume><fpage>77</fpage><lpage>86</lpage><year>2015</year><pub-id pub-id-type="doi">10.1007/s11010-014-2264-3</pub-id></element-citation></ref>
<ref id="b34-ijo-49-06-2538"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jing</surname><given-names>Z</given-names></name><name><surname>Sui</surname><given-names>X</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>W</given-names></name></person-group><article-title>SKF-96365 activates cytoprotective autophagy to delay apoptosis in colorectal cancer cells through inhibition of the calcium/CaMKII&#x003B3;/AKT-mediated pathway</article-title><source>Cancer Lett</source><volume>372</volume><fpage>226</fpage><lpage>238</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.canlet.2016.01.006</pub-id><pub-id pub-id-type="pmid">26803057</pub-id></element-citation></ref>
<ref id="b35-ijo-49-06-2538"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsin</surname><given-names>IL</given-names></name><name><surname>Ou</surname><given-names>CC</given-names></name><name><surname>Wu</surname><given-names>MF</given-names></name><name><surname>Jan</surname><given-names>MS</given-names></name><name><surname>Hsiao</surname><given-names>YM</given-names></name><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Ko</surname><given-names>JL</given-names></name></person-group><article-title>GMI, an immunomodulatory protein from Ganoderma microsporum, potentiates cisplatin-induced apoptosis via autophagy in lung cancer cells</article-title><source>Mol Pharm</source><volume>12</volume><fpage>1534</fpage><lpage>1543</lpage><year>2015</year><pub-id pub-id-type="doi">10.1021/mp500840z</pub-id><pub-id pub-id-type="pmid">25811903</pub-id></element-citation></ref>
<ref id="b36-ijo-49-06-2538"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Sheng</surname><given-names>X</given-names></name><name><surname>Tai</surname><given-names>G</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name></person-group><article-title>Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation</article-title><source>Cell Death Dis</source><volume>7</volume><fpage>e2334</fpage><year>2016</year><pub-id pub-id-type="doi">10.1038/cddis.2016.234</pub-id><pub-id pub-id-type="pmid">27512955</pub-id><pub-id pub-id-type="pmcid">5108320</pub-id></element-citation></ref>
<ref id="b37-ijo-49-06-2538"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>MM</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Khan</surname><given-names>O</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Hori</surname><given-names>T</given-names></name><name><surname>Yun</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>AK</given-names></name><name><surname>Amin</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>CD</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Autophagosomal membrane serves as platform for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis</article-title><source>J Biol Chem</source><volume>287</volume><fpage>12455</fpage><lpage>12468</lpage><year>2012</year><pub-id pub-id-type="doi">10.1074/jbc.M111.309104</pub-id><pub-id pub-id-type="pmid">22362782</pub-id><pub-id pub-id-type="pmcid">3320995</pub-id></element-citation></ref>
<ref id="b38-ijo-49-06-2538"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Lei</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Nice</surname><given-names>EC</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name></person-group><article-title>Redox signaling: Potential arbitrator of autophagy and apoptosis in therapeutic response</article-title><source>Free Radic Biol Med</source><volume>89</volume><fpage>452</fpage><lpage>465</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.08.030</pub-id><pub-id pub-id-type="pmid">26454086</pub-id></element-citation></ref>
<ref id="b39-ijo-49-06-2538"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Loh</surname><given-names>K</given-names></name><name><surname>Yap</surname><given-names>YS</given-names></name></person-group><article-title>PI3K/Akt/mTOR inhibitors in breast cancer</article-title><source>Cancer Biol Med</source><volume>12</volume><fpage>342</fpage><lpage>354</lpage><year>2015</year></element-citation></ref>
<ref id="b40-ijo-49-06-2538"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janku</surname><given-names>F</given-names></name><name><surname>Kaseb</surname><given-names>AO</given-names></name><name><surname>Tsimberidou</surname><given-names>AM</given-names></name><name><surname>Wolff</surname><given-names>RA</given-names></name><name><surname>Kurzrock</surname><given-names>R</given-names></name></person-group><article-title>Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing</article-title><source>Oncotarget</source><volume>5</volume><fpage>3012</fpage><lpage>3022</lpage><year>2014</year><pub-id pub-id-type="doi">10.18632/oncotarget.1687</pub-id><pub-id pub-id-type="pmid">24931142</pub-id><pub-id pub-id-type="pmcid">4102787</pub-id></element-citation></ref>
<ref id="b41-ijo-49-06-2538"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>You</surname><given-names>Q</given-names></name><name><surname>Hua</surname><given-names>D</given-names></name><name><surname>Cai</surname><given-names>D</given-names></name></person-group><article-title>Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway</article-title><source>Int J Immunopathol Pharmacol</source><volume>28</volume><fpage>362</fpage><lpage>373</lpage><year>2015</year><pub-id pub-id-type="doi">10.1177/0394632015598849</pub-id><pub-id pub-id-type="pmid">26246196</pub-id></element-citation></ref>
<ref id="b42-ijo-49-06-2538"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Aita</surname><given-names>Y</given-names></name><name><surname>Ishii</surname><given-names>KA</given-names></name><name><surname>Ikeda</surname><given-names>T</given-names></name><name><surname>Isobe</surname><given-names>K</given-names></name><name><surname>Kawakami</surname><given-names>Y</given-names></name><name><surname>Shimano</surname><given-names>H</given-names></name><name><surname>Hara</surname><given-names>H</given-names></name><name><surname>Takekoshi</surname><given-names>K</given-names></name></person-group><article-title>Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD</article-title><source>Am J Physiol Endocrinol Metab</source><volume>302</volume><fpage>E615</fpage><lpage>E625</lpage><year>2012</year><pub-id pub-id-type="doi">10.1152/ajpendo.00035.2011</pub-id></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-ijo-49-06-2538" position="float">
<label>Figure 1</label>
<caption>
<p>Sal B suppresses the growth of HCC cells. (A) Inhibitory effect of Sal B on SK-Hep-1 and Bel-7404 cells. The percentage of viable cells was measured by the MTS assay. (B) Sal B impairs the colony-forming ability of HCC cells <italic>in vitro</italic>. The control cells are significantly more efficient in forming colonies than the Sal B-treated cells. (C) The total number of colonies, each containing &gt;50 cells, was determined. (D) Cytotoxicity of Sal B on normal human liver cells. After treatment with Sal B for 48 h, the percentage of viable HL-7702 cells was measured by the MTS assay. <sup>**</sup>P&lt;0.01, <sup>***</sup>P&lt;0.001. All data are representative of three independent experiments.</p></caption>
<graphic xlink:href="IJO-49-06-2538-g00.gif"/></fig>
<fig id="f2-ijo-49-06-2538" position="float">
<label>Figure 2</label>
<caption>
<p>Sal B induces apoptosis in HCC cells. Cells were treated with Sal B for 48 h before staining with Annexin V (AV) and propidium iodide (PI) (A), and the apoptotic rates were determined by flow cytometry (B). (C) Cells were treated with 200 &#x003BC;M Sal B for the indicated intervals before staining with AV and PI, and the apoptotic rates were determined by flow cytometry. (D) Cells were treated with Sal B for 48 h before staining with JC-1, and the mitochondrial membrane potential was evaluated by flow cytometry. (E) The expression of apoptosis-associated proteins in cells treated with Sal B for 24 h. Relative quantity of proteins were calculated by ImageJ densitometric analysis and normalized by GAPDH. <sup>*</sup>P&lt;0.05, <sup>**</sup>P&lt;0.01, <sup>***</sup>P&lt;0.001. The data are representative of three independent experiments.</p></caption>
<graphic xlink:href="IJO-49-06-2538-g01.gif"/></fig>
<fig id="f3-ijo-49-06-2538" position="float">
<label>Figure 3</label>
<caption>
<p>TEM depicting ultrastructures of autophagosome in HCC cells treated with Sal B. (A) Numerous autophagosomes appeared in cells treated with 200 &#x003BC;M Sal B for 24 h. Scale bar, 1 &#x003BC;m. (B) The number of autophagosomes was calculated by continuous counts within 10 fields under high resolution. The data are representative of three independent experiments.</p></caption>
<graphic xlink:href="IJO-49-06-2538-g02.gif"/></fig>
<fig id="f4-ijo-49-06-2538" position="float">
<label>Figure 4</label>
<caption>
<p>Effect of Sal B on LC3 processing. (A) Immunoblotting for p62, Beclin-1, and LC3 using lysates from cells treated with Sal B for 24 h. Relative quantity of proteins were calculated by ImageJ densitometric analysis and normalized by GAPDH. (B) Cells were treated with DMSO or 200 &#x003BC;M Sal B for 48 h before they were labeled with fluorescence and imaged by fluorescence microscope. Green, FITC-labeled LC3. Red, LysoTracker-labeled lysosome. Blue, DAPI-labeled nuclei. (C) Cells were treated with DMSO or 200 &#x003BC;M Sal B for the indicated intervals before they were labeled with fluorescence and imaged by fluorescence microscope. The percentage of puncta-positive cells was quantified by automated image acquisition and analysis using a threshold of &gt;5 dots/cell. <sup>***</sup>P&lt;0.001. The data are representative of three independent experiments.</p></caption>
<graphic xlink:href="IJO-49-06-2538-g03.gif"/></fig>
<fig id="f5-ijo-49-06-2538" position="float">
<label>Figure 5</label>
<caption>
<p>Inhibition of autophagy attenuates Sal B-induced apoptosis in HCC cells. (A) Cells were treated with 200 &#x003BC;M Sal B in the presence or absence of CQ (5 &#x003BC;M) or 3-MA (5 mM) for 48 h. Apoptotic rate was measured by flow cytometry. (B) Cells were transfected with siRNA against Beclin-1 for 24 h, then treated with Sal B for 48 h. Apoptotic rate was measured by flow cytometry. (C) Immunoblotting for PARP, cleaved caspase-3 and LC3 using lysates from cells treated with 200 &#x003BC;M Sal B in the presence or absence of 3-MA. Relative quantity of proteins were calculated by ImageJ densitometric analysis and normalized by GAPDH. <sup>*</sup>P&lt;0.05, <sup>**</sup>P&lt;0.01. The data are representative of three independent experiments.</p></caption>
<graphic xlink:href="IJO-49-06-2538-g04.gif"/></fig>
<fig id="f6-ijo-49-06-2538" position="float">
<label>Figure 6</label>
<caption>
<p>AKT signaling is a critical mediator in regulating Sal B-mediated biological effects. (A) Immunoblotting for phospho-AKT, mTOR, S6K, 4EBP1, total AKT, and mTOR in cells treated with Sal B for 24 h. Relative quantity of proteins was calculated by ImageJ densitometric analysis and normalized by GAPDH. After transient overexpression of AKT, cells were treated with Sal B, and then cell viability (B) and apoptotic rate (C) were determined by MTS assay or flow cytometry. (D) Autophagy and apoptosis-associated proteins, including LC3, cleaved PARP, and total AKT were analyzed by immunoblotting. Relative quantity of proteins were calculated by ImageJ densitometric analysis and normalized by GAPDH. <sup>*</sup>P&lt;0.05, <sup>**</sup>P&lt;0.01. The data are representative of three independent experiments.</p></caption>
<graphic xlink:href="IJO-49-06-2538-g05.gif"/></fig>
<fig id="f7-ijo-49-06-2538" position="float">
<label>Figure 7</label>
<caption>
<p>Overexpression of AKT inhibits Sal B-induced autophagy. (A) After transient transfection of AKT expression plasmid, cells were treated with 200 &#x003BC;M Sal B for 24 h. Then, the cells were labeled with fluorescence and imaged by fluorescence microscopy. Green, FITC-labeled LC3. (B) The percentage of puncta-positive cells was quantified by automated image acquisition and analysis using a threshold of &gt;5 dots/cell. <sup>**</sup>P&lt;0.01. The data are representative of three independent experiments.</p></caption>
<graphic xlink:href="IJO-49-06-2538-g06.gif"/></fig></floats-group></article>
